Alliance for Pandemic Preparedness

Result for
Tag: vaccine breakthrough

June 14, 2021

The SARS-CoV-2 MRNA Vaccine Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity

A study of 24 breakthrough SARS-CoV-2 infections among fully vaccinated US Military Health System beneficiaries indicated that most infections (67%) occurred among those without comorbid conditions, 57% reported close contact with a COVID-19 case in the past month, and no case of breakthrough infection resulted in hospitalization. Sequencing from 10 of 13 qPCR-positive specimens indicated…

June 1, 2021

Rate and Risk Factors for Breakthrough SARS-CoV-2 Infection After Vaccination

Breakthrough infection rates were not statistically significantly different by sex or the type of mRNA vaccine administered, according to an analysis of data from a cohort of US veterans (n=14,875). Risk of breakthrough infection increased with age (HR=1.11) and presence of anemia (HR=1.37) and was lower among Black vs white veterans (HR=0.65). The 410 breakthrough…

May 26, 2021

Variants of Concern Are Overrepresented among Post-Vaccination Breakthrough Infections of SARS-CoV-2 in Washington State

[Pre-print, not peer-reviewed] All (n = 20) breakthrough infections detected among fully vaccinated University of Washington healthcare workers involved a variant of concern, compared to a background rate of 68% of community cases being caused by a variant of concern across WA state during the same time period (N=5,174).  Additionally, variants that have been reported…

May 25, 2021

COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021

A total of 10,262 SARS-CoV-2 vaccine breakthrough cases were reported to the CDC across the US as of April 30, 2021, out of approximately 101 million fully vaccinated individuals (0.01%). 27% of vaccine breakthrough infections were asymptomatic. Of the 10% of infected individuals who were hospitalized, of whom 29% were asymptomatic or hospitalized for reasons…

May 20, 2021

Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents

The incidence of SARS-CoV-2 infections among a sample of residents of nursing homes in the US who received an mRNA COVID-19 vaccine (n=18,242, 80% Pfizer-BioNTech vaccine) decreased from 4.5% within 0-14 days after the first dose to 1.4% within 15-28 days after the first dose. Cases occurring 14 or more days after the second dose…

April 27, 2021

Effectiveness of MRNA COVID-19 Vaccines against SARS-CoV-2 Infection in a Cohort of Healthcare Personnel

The COVID-19 mRNA vaccines were up to 96% effective in preventing PCR-confirmed SARS-CoV-2 infection following two doses, according a retrospective cohort study of over 45,000 US healthcare personnel. The Pfizer-BioNTech vaccine accounted for 93% of vaccinations and the Moderna vaccine accounted for 7%. The authors adjusted for age, gender, region, job, and week of vaccination…

April 22, 2021

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

2 SARS-CoV-2 breakthrough infections (infection >= 14 days after the second vaccine dose) were detected in a cohort of 417 employees at the Rockefeller University in New York City. Clinical symptoms of COVID-19 developed 19 days after Patient 1 (51-year-old woman) received their second dose of the Moderna vaccine, and 36 days after Patient 2…